InvestorsHub Logo
Post# of 1625
Followers 187
Posts 22347
Boards Moderated 0
Alias Born 08/14/2011

Re: None

Thursday, 06/20/2024 10:09:21 AM

Thursday, June 20, 2024 10:09:21 AM

Post# of 1625
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBRX News